SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2016
Commission File Number 001-37891
AC IMMUNE SA
EPFL Innovation Park
1015 Lausanne, Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
AC IMMUNE SA
|By:||/s/ Andrea Pfeifer|
|Title: Chief Executive Officer|
|By:||/s/ Martin Velasco|
|November 23, 2016|
|99.1||Press Release dated November 23, 2016|
AC IMMUNE APPOINTS EXPERIENCED LIFE SCIENCE
PROFESSIONAL AS NEW CHIEF FINANCIAL OFFICER
Lausanne, Switzerland, November 23, 2016 AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that it has appointed Mr. Joerg Hornstein as Chief Financial Officer effective Q1 2017. He replaces Mr. George Pavey, who is leaving the Company after its recent successful IPO.
Martin Velasco, Chairman of the Board of Directors of AC Immune, commented, We thank Mr. Pavey for his expertise in helping AC Immune achieve its IPO. As the Company proceeds forward as a publicly-listed entity, with sustainable growth plans, we are delighted to welcome Mr. Hornstein as our new CFO. We will benefit from his extensive experience in the life science industry, including senior financial, controlling and accounting functions in Europe, Asia and the US.
About Joerg Hornstein
Before joining AC Immune, Mr. Hornstein served as Senior Vice President Group Controlling for Unternehmensgruppe Theo Müller based in Luxembourg. Between 2002 and 2013 he worked for Merck KGaA, a leading science and technology company in healthcare, life science and performance materials, where he held various senior finance roles. Amongst others, he was CFO for Mercks operations in Indonesia and Merck Seronos operations in China. Furthermore, he served as Vice President Group Controlling for Merck Group Headquarters in Germany and as Divisional CFO for Merck Millipore in the US. Mr. Hornstein holds an MBA with Distinction from London Business School, UK, and a Bachelor of Business Administration from Baylor University, US.
AC Immune has established a detailed plan to facilitate the transition from Mr. Pavey to Mr. Hornstein joining the Company in Q1 2017.
About AC Immune
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immunes two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimers disease. The Companys pipeline features seven therapeutic and three diagnostic product candidates. The most advanced of these is crenezumab, an anti-Abeta antibody in phase 3 clinical studies that is being advanced by the collaboration partner Genentech, Inc., a wholly owned subsidiary of Roche. Other business partners include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences and Piramal Imaging.
Forward looking statements
This press release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immunes strategies or expectations. In some cases, you can identify these statements by forward-looking words such as may, might, will, should, expects, plans, anticipates, believes, estimates, predicts, projects, potential, outlook or continue, and other comparable terminology. Forward-looking statements are based on managements current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials of AC Immunes product candidates, the clinical utility of AC Immunes product candidates, the timing or likelihood of regulatory filings and approvals, AC Immunes intellectual property position and AC Immunes financial position. These risks and uncertainties also include those described under the captions Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in AC Immunes Registration Statement on Form F-1 and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
For further information please contact:
Prof. Andrea Pfeifer
Chief Executive Officer
Phone: +41-21-345 91 21
Corporate Communications Manager
Phone: +41-21-345 91 34
Mobile: +41 79 926 66 03
Nick Miles/ Toomas Kull
Cabinet Privé de Conseils s.a.
Phone: +41 22 321 45 40
E-mail: firstname.lastname@example.org email@example.com
In the US
The Communications Strategy Group Inc.
Phone: +1 781 631 3117